Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias

Journal of Neuropathology and Experimental Neurology

Volumn 61, Issue 2, 2002, Pages 186-196

  Calon, Frédéric ^a   Birdi, Sam ^a   Rajput, Ali H ^a   Hornykiewicz, Oleh ^a   Bédard, Paul J ^a   Di Paolo, Thérèse ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Basal ganglia; Endogenous opioids; Enkephalin; In situ hybridization; Motor complications; Motor fluctuations; Wearing off

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CATECHOLAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE TRANSPORTER; LEVODOPA; PREPROENKEPHALIN; SELEGILINE;

ADULT; AGED; ARTICLE; AUTOPSY; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DYSKINESIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MOTOR PERFORMANCE; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN;

EID: 0036159502     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/61.2.186     Document Type: Article

References (105)

1. Levodopa motor complications in Parkinson's disease
2. Levodopa-induced dyskinesia: Review, observations, and speculations
3. L-dopa therapy in Parkinson's disease: A critical review of nine years' experience
4. The spectrum of levodopa-induced dyskinesias
5. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: Problems with the current model
6. Primate models of movement disorders of basal ganglia origin
7. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment
8. Dopamine-receptor stimulation: Biobehavioral and biochemical consequences
9. The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia
10. Preprotachykinin-A mRNA expression in the human and monkey brain: An in situ hybridization study
11. Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA
12. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons
13. Temporal dissociation between changes in striatal enkephalin and substance P messenger RNAs following striatal dopamine depletion
14. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain
15. Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine-lesioned rat
16. Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys
17. Striatal changes in preproenkephalin mRNA levels in parkinsonian monkeys
18. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum
19. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP
20. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: Comparison with L-DOPA therapy
21. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists
22. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys
23. Dopaminergic neurons of the substantia nigra modulate preproenkephalin A gene expression in rat striatal neurons
24. Microcircuitry of the direct and indirect pathways of the basal ganglia
25. Striatal enkephalin gene expression does not reflect parkinsonian signs
26. Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: Implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology
27. Striatal expression of substance P and methionin-enkephalin in genes in patients with Parkinson's disease
28. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease
29. Molecular basis of levodopa-induced dyskinesias
30. Adjuncts to dopamine replacement: A pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease
31. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease
32. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias
33. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA
34. Chronic low-dose levodopa therapy in Parkinson's disease: An argument for delaying levodopa therapy
35. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease
36. Evidence to support early levodopa therapy in Parkinson disease
37. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease
38. The role of the Lewy body in idiopathic parkinsonism
39. Ageing and Parkinson's disease: Substantia nigra regional selectivity
40. Levodopa efficacy and pathological basis of Parkinson syndrome
41. Alzheimer's disease and idiopathic Parkinson's disease coexistence
42. Tissue pH as an indicator of mRNA preservation in human post-mortem brain
43. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys
44. Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121
45. GABA receptors and levodopa-induced motor complications in Parkinson disease
46. Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA
47. Multiple opioid receptors: Ligand selectivity profiles and binding site signatures
48. Regulation of opioid receptor activities
49. Investigating levodopa-induced dyskinesias in the parkinsonian primate
50. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat
51. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
52. Prefrontal corticostriatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum
53. Differential expression of preproenkephalin and preprodynorphin mRNAs in striatal neurons: High levels of preproenkephalin expression depend on cerebral cortical afferents
54. Acute treatment with the N-methyl-D-aspartate receptor antagonist MK- 801: Effect of concurrent administration of haloperidol or scopolamine on preproenkephalin mRNA levels of the striatum and nucleus accumbens of the rat brain
55. Levodopa-induced dyskinesia: A pathological form of striatal synaptic plasticity?
56. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications
57. Modulation of levodopa-induced motor response complications by NMDA antagonists in Parkinson's disease
58. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys
59. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys
60. New use for an old drug: Amantadine benefits levodopa-induced dyskinesia
61. Amantadine ameliorates levodopa induced dsykinesia
62. The transcriptional regulation of the preproenkephalin gene
63. DeltaFosB: A molecular mediator of long-term neural and behavioral plasticity
64. Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum
65. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons
66. Distribution, biochemistry and function of striatal adenosine A2A receptors
67. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys
68. Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
69. Pre- and postmortem influences on brain RNA
70. Terminal coma affects messenger RNA detection in post mortem human temporal cortex
71. Presynaptic mu and delta opioid receptor modulation of GABAA IPSCs in the rat globus pallidus in vitro
72. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus
73. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: A 33P in situ hybridization study
74. The functional anatomy of basal ganglia disorders
75. Effects of riluzole on the electrophysiological activity of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey
76. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism
77. Activity of pallidal neurons in the monkey during dyskinesia induced by injection of bicuculline in the external pallidum
78. Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias
79. Endomorphin-1: Induction of motor behavior and lack of receptor desensitization
80. Organization of the basal ganglia: The importance of axonal collateralization
81. Single striatofugal axons arborizing in both pallidal segments and in the substantia nigra in primates
82. Striatal neuropeptide levels in Parkinson's disease patients
83. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea
84. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease
85. Parkinson's disease affects differently Met5- and Leu5-enkephalin in the human brain
86. Dopamine dependent decrease in enkephalin and substance P levels in basal ganglia regions of postmortem parkinsonian brains
87. Subgroups of parkinsonian patients differentiated by peptidergic immunostaining of caudate nucleus biopsies
88. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson's disease and striatonigral degeneration
89. Immunocytochemical studies of substance P and Met-enkephalin in the basal ganglia and substantia nigra in Huntington's, Parkinson's and Alzheimer's diseases
90. Parallel alterations in Met-enkephalin and substance P levels in medial globus pallidus in Parkinson's disease patients
91. Chronic MPTP treatment reduces substance P and met-enkephalin content in the basal ganglia of the marmoset
92. Primate model of Parkinson's disease: Alterations in multiple opioid systems in the basal ganglia
93. Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset
94. Levels of Met-enkephalin, Leuenkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment
95. Met-enkephalin immunoreactivity in the basal ganglia in symptomatic and asymptomatic MPTP-exposed monkeys: Correlation with degree of parkinsonian symptoms
96. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP
97. Effects of dopamine denervation on striatal peptide expression in parkinsonian monkeys
98. Effect of naloxone on the "on-off" syndrome in patients receiving long-term levodopa therapy
99. Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease
100. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys
101. Effect of an opiate antagonist on movement disorders
102. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
103. Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica
104. Pre- and postsynaptic inhibition by opioids in rat striatum